Outcomes of prolonged support on surgically implanted microaxial left ventricular assist devices for refractory cardiogenic shock Article Swipe
Related Concepts
Medicine
Impella
Cardiogenic shock
Interquartile range
Destination therapy
Internal medicine
Cohort
Ventricular assist device
Incidence (geometry)
Retrospective cohort study
Cardiology
Surgery
Refractory (planetary science)
Heart failure
Myocardial infarction
Astrobiology
Physics
Optics
Iris Feng
,
Gabriel Dardik
,
Yuji Kaku
,
Yanling Zhao
,
H. Carmen
,
John DePaolo
,
Marisa Cevasco
,
Mauer Biscotti
,
Joyce Wald
,
J. Fried
,
Koji Takeda
·
YOU?
·
· 2025
· Open Access
·
· DOI: https://doi.org/10.1016/j.xjon.2025.03.023
· OA: W4410035238
YOU?
·
· 2025
· Open Access
·
· DOI: https://doi.org/10.1016/j.xjon.2025.03.023
· OA: W4410035238
Extended Impella 5.5 device support beyond 14 days was not associated with increased incidence of mortality, major bleeding, or stroke in our study, and may be effective for patients requiring extended ventricular assist device support as bridge to heart transplant.
Related Topics
Finding more related topics…